| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Animal: DNA Viruses |
Departments of Microbiology and Immunology1 and Medicine2, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Author for correspondence: Barney Graham. Present address: Vaccine Research Center, NIAID/NIH, Building 40, Room 2502, 40 Convent Drive, MSC 3017, Bethesda, MD 20892-3017, USA. Fax +1 301 480 2771. e-mail bgraham{at}nih.gov
Recombinant vaccinia viruses are well-characterized tools that can be used to define novel approaches to vaccine formulation and delivery. While vector co-expression of immune mediators has enormous potential for optimizing the composition of vaccine-induced immune responses, the impact on antigen expression and vector antigenicity must also be considered. Co-expression of IL-4 increased vaccinia virus vector titres, while IFN-
co-expression reduced vaccinia virus replication in BALB/c mice and in C57BL/6 mice infected with some recombinant viruses. Protection against respiratory syncytial virus (RSV) challenge was similar in mice immunized with vaccinia virus expressing RSV G glycoprotein and IFN-, even though the replication efficiency of the vector was diminished. These data demonstrate the ability of vector-expressed cytokine to influence the virulence of the vector and to direct the development of selected immune responses. This suggests that the co-expression of cytokines and other immunomodulators has the potential to improve the safety of vaccine vectors while improving the immunogenicity of vaccine antigens.
This article has been cited by other articles:
|
|
 |
|
  T. R. Johnson, M. E. Rothenberg, and B. S. Graham Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein J. Leukoc. Biol., September 1, 2008; 84(3): 748 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Day, I. A. Ramshaw, A. J. Ramsay, and C. Ranasinghe Differential Effects of the Type I Interferons {alpha}4, {beta}, and {epsilon} on Antiviral Activity and Vaccine Efficacy J. Immunol., June 1, 2008; 180(11): 7158 - 7166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. McCurdy, J. A. Rutigliano, T. R. Johnson, M. Chen, and B. S. Graham Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4 J. Virol., November 15, 2004; 78(22): 12471 - 12479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Johnson, S. M. Varga, T. J. Braciale, and B. S. Graham V{beta}14+ T Cells Mediate the Vaccine-Enhanced Disease Induced by Immunization with Respiratory Syncytial Virus (RSV) G Glycoprotein but Not with Formalin-Inactivated RSV J. Virol., August 15, 2004; 78(16): 8753 - 8760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Johnson, R. A. Parker, J. E. Johnson, and B. S. Graham IL-13 Is Sufficient for Respiratory Syncytial Virus G Glycoprotein-Induced Eosinophilia After Respiratory Syncytial Virus Challenge J. Immunol., February 15, 2003; 170(4): 2037 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Plotnicky-Gilquin, D. Cyblat-Chanal, J.-P. Aubry, T. Champion, A. Beck, T. Nguyen, J.-Y. Bonnefoy, and N. Corvaia Gamma Interferon-Dependent Protection of the Mouse Upper Respiratory Tract following Parenteral Immunization with a Respiratory Syncytial Virus G Protein Fragment J. Virol., September 11, 2002; 76(20): 10203 - 10210. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
